After Robert W. Baird and William Blair gave Rocket Pharmaceuticals (NASDAQ: RCKT) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Yaron Werber maintained a Buy rating on Rocket Pharmaceuticals today. The company’s shares closed last Monday at $25.58, close to its 52-week high of $27.50.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 19.5% and a 70.8% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Orchard Therapeutics.
Currently, the analyst consensus on Rocket Pharmaceuticals is a Strong Buy with an average price target of $38.67, representing a 91.9% upside. In a report issued on December 6, Chardan Capital also reiterated a Buy rating on the stock with a $30.00 price target.
The company has a one-year high of $27.50 and a one-year low of $10.75. Currently, Rocket Pharmaceuticals has an average volume of 233.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms.